C4 Therapeutics CCCC Institutional Ownership

C4 Therapeutics, Inc. (NASDAQ:CCCC) has 150 institutional investors with active 13F positions as of June 2026.

• Their combined ownership stood at 90.7% of outstanding shares in June 2026, up from 67.0% in March 2026.
• Their total shares held in CCCC increased 44.33% quarter over quarter, and separately, investors owning C4 Therapeutics increased 47.06% from a year ago.
• Of these 150 holders, 108 added to their stakes in C4 Therapeutics, 26 trimmed positions, and 16 made no changes.
• Institutional investors collectively held 118.5Mn shares in C4 Therapeutics as of June 2026, up by 36.4Mn shares quarter on quarter, and up 68.53Mn shares year over year.
• Morgan Stanley leads ownership in CCCC with 8.87Mn shares as of June 30, 2026, equal to 6.78% of outstanding shares.
• The biggest buyers of C4 Therapeutics for the quarter ending June 2026 included BlackRock, Inc. (5.85Mn), Squadron Capital Management LLC (4.95Mn), Ikarian Capital, LLC (2.43Mn), Candriam S.C.A. (1.8Mn), State Street Corp (1.73Mn).
• The largest sales of CCCC for the quarter ending June 2026 came from RENAISSANCE TECHNOLOGIES LLC (1.27Mn), MILLENNIUM MANAGEMENT LLC (1.18Mn), JANE STREET GROUP, LLC (944.15K), Soleus Capital Management, L.P. (425.96K), Wells Fargo & Company/Mn (415.21K).
• C4 Therapeutics's 10 largest shareholders as of June 2026 include Morgan Stanley (8.87Mn), RA CAPITAL MANAGEMENT, L.P. (8.0Mn), BlackRock, Inc. (7.9Mn), Lynx1 Capital Management LP (7.33Mn), Squadron Capital Management LLC (7.2Mn), Bain Capital Life Sciences Investors, LLC (7.17Mn), Jpmorgan Chase & Co (4.75Mn), VANGUARD CAPITAL MANAGEMENT LLC (4.42Mn), CITADEL ADVISORS LLC (4.19Mn), Goldman Sachs Group Inc (3.53Mn) per Business Quant data.